In fact, Koike et al. found that recurrence-free survival was favorable in OSCC patients with high FOXP3+ expression in the parenchyma of the invasive front and that FOXP3+ T cells may exert some type of site-specific anti-tumor effects [53]. This evidence concerns the gene FOXP3 and neoplasm.